Pharmacies risk violating civil rights laws if they deny access to drugs that can be used for abortion, HHS says

Pharmacies risk violating civil rights laws if they deny access to drugs that can be used for abortion, HHS says


Shoppers wait in line at the pharmacy of a Walmart store in Charlotte, North Carolina.

Callaghan O’Hare | Bloomberg | Getty Images

The Health and Human Services Department on Wednesday warned U.S. retail pharmacies that they risk violating civil rights law if they deny access to medication used in abortions under certain circumstances.

The HHS Office for Civil Rights said pharmacies cannot deny access to prescription medication used for reproductive health-care on the basis of the customer’s sex, pregnancy status and other protected groups under federal civil rights law.

This may include the prescription of the abortion pill, mifepristone used in combination with misoprostol, to assist with first-trimester miscarriages. The medication can also be used to terminate an unwanted pregnancy, according to HHS guidance issued to the nation’s 60,000 retail pharmacies.

HHS also said pharmacies risk violating civil rights law if they refuse to fill a prescription for methotrexate to halt ectopic pregnancies.

People who believe a pharmacy is discriminating against them can file a complaint with the HHS Office of Civil rights, an official at the department told reporters on a call Wednesday. Complaints will be reviewed on a case by case basis, the official said.

“The Department is committed to improving maternal health — including for individuals who experience miscarriages — and vigorous enforcement of our civil rights laws is one way in which we plan to do so,” HHS said in guidance issued to the nation’s 60,000 retail pharmacies.

The Affordable Care Act prohibits recipients of federal financial assistance from discriminating on the basis of sex, race, color, national origin, age and disability. Federal civil rights law prohibits discrimination on the basis of current, past or intended pregnancy as well as medical conditions related to pregnancy, according to HHS.

Medication used to terminate pregnancies has become a flashpoint between the Biden administration and states who are banning abortion in the wake of the Supreme Court overturning Roe v. Wade last month, which protected the procedure as a constitutional right for nearly 50 years.

The FDA approved mifepristone more than 20 years ago as a safe and effective way to end a pregnancy before 10 weeks. In December, the FDA said it would permanently allow women to receive the pill by mail from licensed health-care providers.

But states that have banned abortion in the wake of the Supreme Court’s ruling have also outlawed the administration of drugs that terminate pregnancies. The abortion bans generally make exceptions for the procedure when the women’s life is in danger.

This is a developing story. Please check back for updates.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More